Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Envarsus versus current tacrolimus practice in de novo kidney transplant recipients
NL-OMON44149Phase 4Withdrawn
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Dec 2015
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of tacrolimus in end-stage kidney disease (ESKD) and kidney transplant immunosuppression (2 arms), sponsored by Chiesi Farmaceutici S.p.A. Primary endpoint: Average tacrolimus total daily dose. Planned start Dec 2015; status: withdrawn.
02
Drugs
tacrolimus
03
Conditions
end-stage kidney disease (ESKD)kidney transplant immunosuppression
Beyond the preview
Go deeper on NL-OMON44149.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44149.